Grand Pharmaceutical Group Limited

512 BMG210A71016

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
4.93 ^HKD	-0.40%		+2.28%	+20.54%

Apr. 29	Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	MT
Mar. 27	Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	CI

Grand Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023

August 10, 2023 at 06:42 am EDT

Grand Pharmaceutical Group Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was HKD 5,989.49 million compared to HKD 5,212.58 million a year ago. Net income was HKD 1,029.35 million compared to HKD 710.41 million a year ago.

Basic earnings per share from continuing operations was HKD 0.2912 compared to HKD 0.2016 a year ago.

Latest news about Grand Pharmaceutical Group Limited

Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	Apr. 29	MT
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	Mar. 27	CI
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug	Mar. 24	MT
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors	Mar. 24	CI
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024	Mar. 19	CI
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication	Mar. 08	MT
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial	Mar. 08	MT
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884	Mar. 07	CI
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China	Feb. 08	MT
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator	Jan. 24	MT
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan	Jan. 16	MT
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops	Dec. 27	MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA	Dec. 27	CI
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million	Dec. 22	MT
Grand Pharmaceutical's Subsidiaries to Resell Sirtex's Products for 166.5 Million Yuan	Dec. 18	MT
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan	Dec. 13	MT
Grand Pharmaceutical Unit Enrolls, Doses 1st Patient in Sepsis Drug Phase 2 Trial	Nov. 27	MT
Grand Pharma Gets China's Nod for Phase 1 Clinical Trial for Tumor Vaccine	Nov. 03	MT
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01	Nov. 02	CI
Grand Pharmaceutical Arm BlackSwan Commercializes Liquid Embolic in U.S	23-10-30	MT
Grand Pharmaceutical Doses First Patient in China Clinical Study of Post-Cataract Surgery Eye Drops	23-10-24	MT
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing	23-10-24	CI
Grand Pharmaceutical Meets Primary Endpoint of Phase 3 China Trial of Nasal Spray	23-09-13	MT
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint	23-09-13	CI

Chart Grand Pharmaceutical Group Limited

Duration

Period

Chart Grand Pharmaceutical Group Limited

More charts

Company Profile

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a Hong Kong-based investment holding company principally engaged in the manufacturing and sales of pharmaceutical preparations and medical devices. The Company is principally engaged in manufacturing and sales of pharmaceutical preparations and medical devices, bio-technology products, nutrition products, specialized pharmaceutical raw materials and other products. The main products of the Company cover the anti-tumor, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ear-nose-throat (ENT), bio-health products and specialized pharmaceutical ingredients.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Grand Pharmaceutical Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.93

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GRAND PHARMACEUTICAL GROUP LIMITED	+20.54%	2.21B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals